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1. Introduction 
Dibenzo[b,f][1,4]oxazepine derivatives are attractive 
compounds that recently have attracted huge attention from the 
pharmaceutical industry due to the wide spectrum of biological 
activities that present such compounds.1 Among compounds 
containing the dibenzoxazepine scaffold are non-nucleoside HIV-
1 reverse transcriptase inhibitors,2 antidepressants,3 analgesics,4 
anxiolytics5 and a lachrymatory agent,6 as well as a histamine H4 
receptor agonist,7 PGE28 and calcium9 antagonists. In this 
context, 11-substituted-10,11-dihydrodibenzo[b,f][1,4]oxazepine 
derivatives play an important role in medicinal chemistry and 
several derivatives have shown interesting biological activities 
(Figure 1), therefore their synthesis are of great interest in 
organic synthetic chemistry.10 However, catalytic asymmetric 
methodologies for the synthesis of this kind of compounds are 
scarce in the literature. So far, only iridium-catalyzed asymmetric 
hydrogenation of the corresponding seven-membered cyclic 
ketimines,11 as well as enantioselective Mannich,12 aza-
Reformatsky,13 alkynylation14 and propargylation15 reactions of 
the seven membered cyclic aldimines have been described. 
Therefore, the development of new methodologies to synthesize 
optically pure 11-substituted-10,11-
dihydrodibenzo[b,f][1,4]oxazepine derivatives is highly desirable 
for synthetic organic chemistry. 
 
Figure 1. Examples of 11-substituted-10,11-
dihydrodibenzo[b,f][1,4]oxazepine derivatives  with biological 
activities. 
 
The catalytic asymmetric addition reactions of organometallic 
reagents to imines are a central processes in synthetic chemistry 
to prepare chiral amines,16 which are important building blocks 
for pharmaceutical and medicinal chemistry.17 In this context, the 
catalytic asymmetric addition of dialkylzinc reagents to imines is 
a convenient methodology to prepare chiral amines.18 Several 
examples of the enantioselective addition of organozinc reagents 
to acyclic imines have been described in the literature.19 
However, the corresponding addition of dialkylzinc reagents to 
cyclic imines remains unexplored, to the best of our knowledge 
(Scheme 1). Hence, we present our results on the enantioselective 
addition of Et2Zn to dibenzo[b,f][1,4]oxazepine derivatives, as a 
seven-membered cyclic imine, catalyzed by a (R)-VAPOL-Zn(II) 
complex in order to prepare chiral 11-ethyl-10,11-
dihydrodibenzo[b,f][1,4]oxazepine derivatives with good yields 
and moderate enantioselectivities. 
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Various substituted dibenzo[b,f][1,4]oxazepines underwent an enantioselective alkylation with
Et2Zn catalyzed by a (R)-VAPOL-Zn(II) complex. The corresponding chiral 11-ethyl-10,11-
dihydrodibenzo[b,f][1,4]oxazepine derivatives were obtained with good yields and moderate
enantioselectivities. This represents the first example of enantioselective addition of Et2Zn to 
cyclic aldimines. 





































Scheme 1. Enantioselective addition of Et2Zn to imines. 
2. Results and discussion 
Optimization studies were performed with the alkylation 
reaction of seven-membered cyclic imine 1a, as the model 
substrate, with Et2Zn in dichloromethane at room temperature.  
Several chiral Zn(II)-complexes, generated in situ from Et2Zn 
and chiral ligands L (Figure 2), were tested and the results are 
summarized in Table 1. 
 
Figure 2. Chiral ligands evaluated. 
 
First, a family of BINOL ligands (L1-L6, entries 1-6 Table 1) 
were evaluated, and the corresponding amine 3a was obtained, in 
general, with low yields and low enantioselectivities. Though, 
with (R)-6,6’-Br2-BINOL (L2) a promising 50% ee was 
observed. Then, we decided to examine vaulted ligands like (R)-
VAPOL (L7) and (R)-VANOL (L8). The use of L7 as a ligand 
(entry 7), afforded the product 3a with better enantioselectivity 
(61% ee), although the yield was moderate (36%). When (R)-
VANOL (L8) was used as a ligand (entry 8), 3a was afforded in 
40% yield, but almost as a racemic mixture. Subsequently, we 
decided to test different chiral aminoalcohols, such as quinine 
(L9) or diaryl prolinol ligands (L10-L13) used successfully in 
enantioselective zinc mediated reactions,13,20 but the 
enantioselectivities observed were very low. Only Trost ligand21 
L14 (entry 14) gave some asymmetric induction (20% ee). Other 
ligands such chiral α-hydroxyamides L15 (entry 15) and L16 
(entry 16), developed in our research group for the addition of 
organozinc reagents to carbonyl compounds22 were also 
evaluated, but they proved to be unsuccessful ligands in the 
addition of Et2Zn to cyclic imines.  
Table 1. Ligand screening.a 
 
Entry Ligand (20 mol%) Yield (%)b ee (%)c 
1 L1 36 37 
2 L2 34 50 
3 L3 20 14 
4 L4 18 19 
5 L5 16 8 
6 L6 22 18 
7 L7 36 61 
8 L8 40 5 
9 L9 30 5 
10 L10 47 0 
11 L11 53 0 
12 L12 48 1 
13 L13 55 5 
14 L14 48 20 
15 L15 19 11d 
16 L16 33 8 
aReaction conditions: 1a (0.1 mmol), 1M Et2Zn (2) in hexane (0.5 mmol) and 
Ligand L (0.02 mmol) in 2 mL of CH2Cl2 at room temperature for 24 hours. 
bIsolated yield after column chromatography. 
cEnantiomeric excess were determined by HPLC using chiral stationary 
phase.  
dOpposite enantiomer was obtained. 
Table 2. Solvent screening.a 
 
Entry Solvent Yield (%)b ee (%)c 
1 CH2Cl2 53 61 
2 ClCH2CH2Cl 68 38 
3 THF 70 27 
4 MTBE 52 54 
5 iPr2O 49 42 
6 Et2O 53 69 
7 Toluene 49 45 
8 AcOEt 58 44 
aReaction conditions: 1a (0.1 mmol), 1M Et2Zn (2) in hexane (0.5 mmol) and 
Ligand L (0.02 mmol) in 2 mL of solvent at room temperature for 24 hours. 
bIsolated yield after column chromatography. 
cEnantiomeric excess were determined by HPLC using chiral stationary 
phase.  
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With (R)-VAPOL (L7), which gave the best 
enantioselectivity, we decided to continue the optimization 
process testing different solvents (Table 2). Dichloroethane 
provided better conversion but lower enantiomeric excess than 
dichloromethane. With ethereal solvents (THF, MTBE or iPr2O) 
lower levels of enantioselectivity were obtained for compound 
3a. However, when Et2O was used as a solvent an improvement 
in the enantiomeric excess was observed and product 3a was 
afforded in 69% ee (Entry 5, Table 2). Other solvents such 
toluene or AcOEt did not improve the results obtained with Et2O. 
Our efforts to improve the enantiomeric excess of compound 3a 
were unsuccessful, therefore we decided to study the scope of the 
reaction with the conditions shown in entry 6, Table 2.  
 
Scheme 2. Scope of asymmetric addition of Et2Zn to 
dibenzo[b,f][1,4]oxazepine derivatives. 
 
We tested several cyclic seven membered imines containing 
different electron-withdrawing or electron-donating groups with 
Et2Zn. The reaction, in general, proceed with good yields (40-
71%) and moderate enantioselectivities (34-70% ee). When the 
substituents are placed in 7-position (3b-3c), the conversion and 
the enantiomeric excess observed were lower. Whilst, when the 
substituents were at 8-position the enantioselectivities were 
around 60%. On the other hand, the electronic character of the 
substituents at 2-position (3g-3i) had an influence in the 
enantioselectivity of the reaction. For example, electron-donating 
groups such methoxy led to the reaction product with 70% ee, 
whilst electron-withdrawing groups such chlorine lowered the 
enantioselectivity of the reaction (34% ee). Finally, naphthyls 
groups were tolerated in the reaction, obtaining the corresponding 
alkylated amines 3k and 3l with moderate enantioselectivities, 
59% ee and 67 % ee respectively. Our efforts to expand our 
methodology to other organozinc reagents were unsuccessful. 
When Me2Zn, Bu2Zn and iPr2Zn were tested under the optimized 
reaction conditions very low conversions to the corresponding 
alkylated products were observed.23 
3. Conclusions 
In summary, we have reported the enantioselective alkylation 
of dibenzo[b,f][1,4]oxazepine derivatives with Et2Zn catalyzed 
by a (R)-VAPOL-Zn(II) complex. This methodology has 
provided an approach to synthesize optically active 11-ethyl-
10,11-dihydrodibenzo[b,f][1,4]oxazepine derivatives with good 
yields (up to 76%) and moderate enantioselectivities (up to 70% 
ee). The present study extends the scope of the catalytic 
asymmetric addition of organometallic reagents to cyclic seven 
membered imines, and represents the first enantioselective 
addition of Et2Zn to cyclic imines. 
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